Lung cancer is the leading cause of cancer death worldwide. Recent data suggest that cyclic nucleotide phosphodiesterases (PDEs) are relevant in various cancer pathologies. Pathophysiological role of phosphodiesterase 4 (PDE4) with possible therapeutic prospects in lung cancer was investigated. We exposed 10 different lung cancer cell lines (adenocarcinoma, squamous and large cell carcinoma) to hypoxia and assessed expression and activity of PDE4 by real-time PCR, immunocytochemistry, western blotting and PDE activity assays. Expression and activity of distinct PDE4 isoforms (PDE4A and PDE4D) increased in response to hypoxia in eight of the studied cell lines. Furthermore, we analyzed various in silico predicted hypoxia-responsive elements (p-HREs) found in PDE4A and PDE4D genes. Performing mutation analysis of the p-HRE in luciferase reporter constructs, we identified four functional HRE sites in the PDE4A gene and two functional HRE sites in the PDE4D gene that mediated hypoxic induction of the reporter. Silencing of hypoxia-inducible factor subunits (HIF1a and HIF2a) by small interfering RNA reduced hypoxic induction of PDE4A and PDE4D. Vice versa, using a PDE4 inhibitor (PDE4i) as a cyclic adenosine monophosphate (cAMP) -elevating agent, cAMP analogs or protein kinase A (PKA)-modulating drugs and an exchange protein directly activated by cAMP (EPAC) activator, we demonstrated that PDE4-cAMP-PKA/EPAC axis enhanced HIF signaling as measured by HRE reporter gene assay, HIF and HIF target genes expression ((lactate dehydrogenase A), LDHA, (pyruvate dehydrogenase kinase 1) PDK1 and (vascular endothelial growth factor A) VEGFA). Notably, inhibition of PDE4 by PDE4i or silencing of PDE4A and PDE4D reduced human lung tumor cell proliferation and colony formation. On the other hand, overexpression of PDE4A or PDE4D increased human lung cancer proliferation. Moreover, PDE4i treatment reduced hypoxia-induced VEGF secretion in human cells. In vivo, PDE4i inhibited tumor xenograft growth in nude mice by attenuating proliferation and angiogenesis. Our findings suggest that PDE4 is expressed in lung cancer, crosstalks with HIF signaling and promotes lung cancer progression. Thus, PDE4 may represent a therapeutic target for lung cancer therapy.
INTRODUCTION
Lung cancer is the leading cause of cancer-related death worldwide. 1 The limited success of classic chemotherapeutics has led to focus on developing rationally targeted therapies aimed at the molecular mechanisms underlying tumorigenesis. Several novel drugs that specifically target these key components have been developed, but have yet to prove their efficacy for routine clinical application. 2, 3 Hence, it is essential to continue the identification of novel regulators of lung tumor growth and tumor microenvironment.
Regulation of cyclic nucleotide signaling is regarded as a composite of multiple component pathways involved in diverse aspects of tumor cell function. [4] [5] [6] [7] The impairment of cyclic adenosine monophosphate (cAMP) or cyclic guanosine monophosphate (cGMP) generation by regulation of phosphodiesterases (PDEs) has been implicated in various cancer pathologies. 8, 9 PDEs are enzymes that regulate cellular levels of cAMP/cGMP by controlling their degradation. These enzymes are classified into 11 families (PDE1-PDE11) based on their sequence similarity, substrate preference and sensitivity to various inhibitors. 10, 11 phosphodiesterase 4 (PDE4), one of 11 PDE enzyme families, specifically catalyzes hydrolysis of cAMP. It has four subtypes (PDE4A, PDE4B, PDE4C and PDE4D) with at least 35 splice variants. PDE4 has a critical role in controlling intracellular cAMP concentrations. 12 Importantly, many tumor cells originating from the central nervous system, lung and breast have PDE4 among all PDEs, as major regulator of cAMP-hydrolyzing activity. 13 Interestingly, PDE4 inhibitors (PDE4i) were shown to inhibit growth and chemotaxis and to increase differentiation and/or apoptosis in pancreatic cancer cells, colon cancer cells and malignant melanoma cells. [14] [15] [16] Inhibition of PDE4 by the selective inhibitor rolipram is shown to suppress tumor growth and augments the anti-tumor effects of chemotherapy and radiation therapy in medulloblastoma, glioblastoma 17 and in several hematological malignancies. 18 Why PDE4 isoforms are overexpressed in so many different tumor types remains elusive, but like other tumorigenesis factors, PDE4 isoforms may be regulated by changes in hypoxia. Adaptation to hypoxia is critical for tumor cell growth and 1 survival. 19 Hypoxia causes upregulation of genes through stabilization of hypoxia-inducible transcription factors (HIFs). HIF1a and HIF2a share common target genes characterized by a consensus hypoxia-responsive element (HRE) , that are involved in cell growth, proliferation and angiogenesis. 20 However, a direct relation between the hypoxia-HIF axis and the PDE4-cAMP axis in malignant cells has not been reported.
We analyzed whether PDE4 expression is induced in hypoxia and involved in lung cancer progression. To evaluate this potential link, we studied the possible HIF dependence of PDE4. Furthermore, we analyzed the functional significance of predicted HREs (p-HREs) of the PDE4A and PDE4D genes. Also, we studied PDE4-cAMP-mediated regulation of HIF and its downstream signaling molecules. In addition, we studied the influence of PDE4 inhibition on proliferation in vitro in a panel of 10 human lung cancer cells and assessed proliferation and angiogenesis in a nude mouse model of adenocarcinoma in vivo.
RESULTS

PDE4 isoform expression increases in response to hypoxia
To determine whether the expression of PDE4 isoforms (PDE4A, PDE4B, PDE4C and PDE4D) is induced in hypoxia, A549 adenocarcinoma cells were exposed to different oxygen concentrations (0.5, 1, 2 and 3% O 2 ) for 12 and 24 h. Compared with PDE4 isoform expression in normoxia, the mRNA levels of both PDE4A and PDE4D increased significantly in response to hypoxia that is, with decreasing concentrations of O 2 ( Figure 1a ). Real-time RT-PCR analysis revealed that PDE4A and PDE4D mRNA was markedly induced by hypoxic exposure for 12 and 24 h (Figure 1a) . However, PDE4B is not expressed and PDE4C mRNA expression was decreased in response to hypoxia (Supplementary Figure 1a) . Importantly, induction of PDE4A and PDE4D mRNA showed oxygen dependency. PDE4A and PDE4D mRNA was markedly induced by 0.5% O 2 , peaked by 1% O 2 and decreased thereafter with increasing O 2 concentrations (2 and 3%). Furthermore, immunoblotting confirmed that the protein levels of PDE4A (PDE4A1 74 kDa) and PDE4D (PDE4D4 105 kDa) were strongly induced by 24 h of exposure to 0.5 and 1% O 2 concentrations ( Figure 1b) .
As strong induction of both isoforms, PDE4A and PDE4D at mRNA and protein level occurred in A549 cells that were exposed to 1% O 2 , further experiments were continued with 1% O 2 concentration. Immunofluorescence intensity measurements confirmed increased PDE4A-and PDE4D-like immunoreactivity in the cytoplasm after 24 h of exposure to hypoxia (Figures 1c-e) . Interestingly, total cAMP-PDE activity was increased almost twofold in response to hypoxia compared with normoxic controls. Using PDE4i, we calculated the relative contribution of PDE4 activity to the total cAMP-PDE activity and found PDE4 to be the major contributor (Figure 1f ). HIF1a or HIF2a is required for the regulation of PDE4A/PDE4D transcription in response to hypoxia Members of the HIF family of transcription factors are the major regulators of hypoxia-induced transcription. Hence, we studied whether hypoxia-mediated upregulation of PDE4 isoforms involves HIF. We examined expression and localization of HIF1a, HIF2a, PDE4A and PDE4D under normoxic and hypoxic conditions in A549 cells. Immunofluorescence analysis showed nuclear accumulation of HIF1a and HIF2a in hypoxia and an increase of PDE4A-and PDE4D-like immunoreactivity primarily in the cytoplasm (Figure 2a) .
Further, we studied whether PDE4A and PDE4D are transcriptional targets of HIF. To delineate, silencing of HIF1a and HIF2a by selective small interfering RNAs (siRNAs) was performed. 21 In accordance, suppression of HIF1a and HIF2a protein expression in A549 cells transfected with selective siRNAs in hypoxia was confirmed by immunoblotting ( Figure 2b ). To determine whether hypoxic regulation of PDE4 involves HIF, we analyzed PDE4A or PDE4D mRNA expression in these transfected cells. Interestingly, we observed a significant downregulation of PDE4A in A549 cells transfected with either HIF1a or HIF2a siRNA, followed by exposure to hypoxia (Figure 2c) . Similarly, PDE4D expression is suppressed by both HIF1a siRNA and HIF2a siRNA, compared with control siRNA (Figure 2c ). Immunofluorescence as well as immunoblotting showed that PDE4A and PDE4D protein levels were significantly reduced after silencing HIF1a or HIF2a under hypoxic conditions (Figures 2d-f ). In addition, selective silencing of HIF1a or HIF2a expression caused a significant reduction of total cAMP-PDE activity as well as PDE4 activity (Figure 2g) , confirming the functional dependence of PDE4 on HIF1a.
Hypoxia-HIF regulates PDE4A/PDE4D transcription in response to hypoxia To determine the molecular mechanisms underlying hypoxia-and HIF-induced PDE4A/PDE4D gene expression, we performed in silico analysis to identify rHRE located in the 5 0 regulatory regions of PDE4A and PDE4D (Figure 3a) . We identified 13 p-HREs in PDE4A and 3 p-HREs in PDE4D. The p-HREs in PDE4A gene are located at À 8210, À 7133, À 6970, À 6851, À 6387, À 6159, À 5460, À 5016, À 3439, À 2425, À 2063, À 869 and À 724, relative to the start codon site of PDE4A (Figure 3a) . In PDE4D they are located at À 7740, À 4537 and À 734 (Figure 3a) . To verify that the p-HRE sites that are functional, we performed site-directed mutagenesis and generated a series of mutation constructs. To attain, we first assessed the hypoxic responsiveness of control plasmid (5 Â PGK-HRE HSV TKMP promoter) (Figure 3c ). Further, 5 Â PGK-HRE's in control vector (5 Â PGK-HRE HSV TKMP promoter) were replaced by the p-HRE regions (p-wtHRE; NCGTG ± 12N) or its mutated control sequences (p-mutHRE; NAAAG±12N) ( Figure 3b ).
Transient transfection of p-wtHRE or p-mutHRE luciferase reporter constructs into A549 cells in presence of normoxia/ hypoxia demonstrated that only p-wtHRE constructs at À 724, À 869, À 2063 and À 5460 caused a significant induction of luciferase activity only in presence of hypoxia. Importantly, hypoxia was not able to stimulate luciferase activity of a construct where the p-HRE in the PDE4A/PDE4D promoter was mutated (p-mutHRE; Figure 3d ). These results suggest that four HRE sites in PDE4A promoter are functional. On the other hand, two out of three predicted sites in PDE4D promoter were functional. p-wtHRE constructs at À 4537 and À 7740 showed 2-3 fold induction of luciferase activity in presence of hypoxia. However, no induction was observed when cells were transfected with the respective p-mutHRE (Figure 3e ). PDE4-cAMP axis regulates HIF transcription and HIF target genes To investigate whether PDE4 regulates HIF-dependent signaling, A549 cells were transiently transfected with an HRE-dependent luciferase reporter plasmid and cultured under normoxic or hypoxic conditions in the absence or presence of PDE4i. Hypoxia caused a 20-fold induction of HRE-dependent luciferase activity that was reduced by addition of PDE4i (Figure 4a ). Importantly, PDE4i also significantly reduced protein expression of HIF1a and HIF2a under hypoxic condition (Figure 4b) .
To delineate the downstream signaling involved in PDE4-mediated HIF regulation, we examined the effect of forskolin (a cAMP-elevating agent) and 8-Br-cAMP (a cell-permeable, nonhydrolyzable cAMP analog) on HRE-dependent luciferase activity. Treatment with forskolin/8-Br-cAMP significantly decreased hypoxia-induced luciferase activity in A549 cells (Figures 4c and d) .
Having confirmed cAMP involvement, we further assessed cAMP-mediated signaling pathways, namely protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC), using specific activators and inhibitors. Both PKA and EPAC activators (6-Benz-cAMP and 8-CPT-2 0 -O-Me-cAMP) decreased HRE-dependent luciferase activity under hypoxic conditions in A549 cells (Figures 4e and f) . Interestingly, co-treatment with the PKA inhibitor KT5720 and PDE4i did not alter hypoxia-induced HRE-dependent luciferase activity (Supplementary Figure 2) . Moreover, PDE4i significantly decreased the expression of HIFdependent target genes. Hypoxia-induced mRNA expression of lactate dehydrogenase A (LDHA), pyruvate dehydrogenase kinase 1 (PDK1) and vascular endothelial growth factor (VEGF) decreased PDE4 inhibition reduces lung cancer cell proliferation and VEGF secretion As PDE4i regulates VEGF expression, we determined the effects of PDE4i on VEGF secretion. As expected, VEGF concentration in culture supernatants, which was enhanced under hypoxic conditions, was significantly reduced by PDE4 inhibition (Supplementary Figure 3) . To confirm the role of PDE4 in proliferation of human lung tumor cells, A549 cells in normoxia or hypoxia were treated with PDE4i. Cell proliferation was quantified by incorporation of [ 3 H]thymidine or BrdU. A549 cells exposed to hypoxia for 24 h incorporated significantly more Given this marked effect of PDE4i on cell proliferation under hypoxic conditions, we then investigated the effect of PDE4 inhibition on the expression of key control elements of the G1/Sphase transition, including cyclin B1, cyclin E and CDK inhibitor p27, in A549 cells treated with PDE4i. As shown in Supplementary  Figure 4 , PDE4i treatment decreased the expression of cyclins B1 and E compared with control cells. By contrast, p27 expression level did not change significantly (Supplementary Figure 4) .
The growth inhibition of PDE4i on lung cancer cells was also assessed using colony formation assays. Importantly, the results were similar to those obtained from the proliferation assays. Compared with the control, PDE4i decreased the number of colonies in a concentration-dependent manner. PDE4i decreased the colony numbers by 75% (10 mM) and 57% (50 mM), respectively (Figures 5c and d) .On the other hand, PDE4i strongly decreased the colony numbers in A549 cells exposed to hypoxia that is, by 67% (10 mM) and 45% (50 mM), respectively (Figures 5c and d ).
PDE4 inhibits proliferation and HIF signaling of several human lung cancer cell lines We next investigated whether PDE4 activation, the anti-proliferative effects of PDE4i as well as the effects of PDE4i on HIF signaling are restricted to A549 cells or have a broader impact on other human non-small-cell lung cancer cells. Investigation of the anti-proliferative effects of PDE4i in nine different human lung cancer cells (five adenocarcinomas, two large cell carcinomas and two squamous cell carcinomas) exposed to normoxia or hypoxia revealed that five of them were highly sensitive to PDE4i (H1299, H1975, H661, A520 and H1437), two of them displayed intermediate sensitivity (H23 and H1650), and two of them were resistant to PDE4i (H460 and H226) (Figures 6a and 7a) . We measured total cAMP-hydrolyzing PDE activity and PDE4 activity in all the nine different human lung cancer cells. In seven of the nine cell lines, PDE4 activity contributed significantly to the total cAMP-PDE activity (Figures 6b and 7b) .
Furthermore, we assessed the influence of PDE4i on protein expression of HIF isoforms and HIF downstream target, VEGF. We observed that HIF1a, HIF2a and VEGF were down regulated by PDE4i in H1299, H661, H1437 and H1975 cells in dose-dependent manner (Figures 6c and 7c ). PDE4i downregulated HIF and VEGF only at a high concentration in H23, H1650 and A520 cells (Figures  6c and 7c) .
PDE4A-or PDE4D-selective siRNA reduces lung cancer cell proliferation To more specifically evaluate the PDE4 inhibition, pooled siRNAs targeting PDE4A and PDE4D were used, that were shown to selectively knock down PDE4A and PDE4D, respectively. 22 Each of PDE4A-and PDE4D-siRNA knocked down the expression of its corresponding endogenous mRNA in hypoxia (Figure 8a ). Downregulation of PDE4A and PDE4D protein expression was also confirmed by immunoblotting (Figure 8b ). Suppression of PDE4A and PDE4D protein expression was also confirmed by immunocytochemistry (Supplementary Figure 5) . Further, to determine the effects on proliferation, PDE4A or PDE4D siRNA was transfected into A549 cells followed by exposure to normoxia or hypoxia for 24 h. Transfection of A549 cells with either PDE4A siRNA or PDE4D siRNA caused a significant decrease in hypoxia-stimulated [ 3 H]thymidine and BrdU incorporation. Control siRNA had no effect on proliferation (Figures 8c and d) . Interestingly, transfection of both PDE4A and PDE4D siRNAs showed additive effects on proliferation suppression compared with PDE4A or PDE4D siRNAs alone (Figure 8b-d) .
PDE4A-or PDE4D overexpression induces lung cancer cell proliferation To unveil that whether PDE4 isoforms itself induces proliferation in A549 cells, A549 cells were transiently transfected with PDE4A, PDE4D or both PDE4A and PDE4D expression plasmid or empty vector. Real-time RT-PCR indicated that PDE4A or PDE4D mRNA was dramatically increased in PDE4 constructs transfected cells compared with empty vector transfected cells (Figure 8e) . Moreover, we observed an overexpression of PDE4A or PDE4D protein in these cells (Figure 8f ). Further assessing whether PDE4 was able to induce proliferation in presence of normoxia/hypoxia in A549 cells, we observed that PDE4A-, PDE4D-overexpression or combination of both caused an increase in both normoxia and hypoxia-stimulated [ 3 H]thymidine and BrdU incorporation (Figures  8g and h) . Under hypoxic conditions the proliferation induced by PDE4A or PDE4D overexpression is much stronger compared with respective normoxic controls (Figures 8g and h ).
PDE4i inhibits A549 tumor xenograft growth in nude mice by altering proliferation and angiogenesis To study the effects of PDE4 inhibition in vivo, A549 cells were injected s.c. into nude mice. When tumor size reached B36 mm 3 , mice were treated with PDE4i at different doses (1, 3 or 6 mg/kg) i.p. every day until day 36. We did not observe any significant change in body weight (Supplementary Figure 6) or any adverse behavioral effects in animals treated with PDE4i compared with the control animals throughout the experiment. Regarding its anticancer efficacy, PDE4i treatment at 3 and 6 mg/kg started showing inhibition of tumor growth at the 8th day of treatment, which became more visible and statistically significant at 24th day (Figure 7a) (left). To further study the significance of our cell culture findings related to growth inhibition by PDE4i in vivo, we performed Ki67 staining in PDE4i-treated tumor tissue. The number of proliferating cells in tumors stained with Ki67 was reduced in PDE4i-treated mice (61.59% in 1 mg/kg; 49.65% in 3 mg/kg and 40.60% in 6 mg/ kg) compared with control mice or mice treated with a placebo (Figures 9b and c) . In addition, analysis of angiogenesis in tumors by staining vessels for CD31 indicated decreased angiogenesis in PDE4i-treated mice compared with control mice or mice treated with a placebo (Figures 9b and d) .
DISCUSSION
We report hypoxia-induced regulation of PDE4 in most lung tumor cell types, including adenocarcinoma, large cell carcinoma and squamous cell carcinoma. Upregulation of PDE4 isoforms (mainly PDE4A and PDE4D) by hypoxia was mediated by HIF1a and HIF2a. Furthermore, PDE4 regulated HIF transcriptional activity via a cAMP-PKA/EPAC-dependent pathway. PDE4 inhibition by rolipram or siRNA-mediated knockdown of PDE4 reduced tumor cell proliferation and altered the expression of cell-cycle genes. PDE4i potently reduced lung tumor growth in A549 lung tumor PDE4 has been reported as a major cAMP-hydrolyzing enzyme in several tumor cell lines. 13 In the current study, we confirmed the leading role of PDE4 in cAMP hydrolysis in several human nonsmall-cell lung cancer cell lines. As it is well known that hypoxia has an important role in lung tumor progression by regulating HIF1 transcription factor. 23, 24 We investigated whether PDE4 isoforms represent a direct target of hypoxia. Indeed, we noted increased mRNA and protein expression of PDE4A and PDE4D isoforms in response to hypoxia, which was confirmed by increased PDE4 activity. Several predicted HREs were identified in the 5 0 regulatory regions of PDE4A and PDE4D. 25 Importantly, generating several wild-type/mutated HRE luciferase reporter constructs, we identified four functional HREs in the PDE4A 5 0 regulatory gene region and two functional HREs in PDE4D 5 0 regulatory gene region. Moreover, we demonstrated that the observed increase in PDE4A and PDE4D levels in hypoxia was dependent on HIF1a and HIF2a, as siRNA-mediated silencing of HIF1a and HIF2a led to decreased expression and activity of PDE4A and PDE4D isoforms.
To our knowledge, only two studies have reported a potential hypoxia-induced activation of PDE4 in nontumorigenic cells. 26, 27 Millan et al. 26 showed a transient upregulation of PDE4B and a sustained upregulation of PDE4A and PDE4D upon exposure of human pulmonary artery smooth muscle cells to hypoxia. 26 Also, Nunes et al. 27 detected enhanced PDE4 activity in the rat carotid body induced by acute hypoxia. Yet, ours is the first study to explicitly address PDE4 induction by hypoxia in lung tumor cells and assess the underlying molecular mechanisms. Intriguingly, we found that PDE4 inhibition decreased HIF transcriptional activity in A549 cells only under hypoxic conditions. This finding was strengthened by decreased protein expression of HIF and mimicked by results obtained from treating hypoxic A549 cells with a cAMP-elevating agent (forskolin), cAMP analog (8-BrcAMP), PKA activator (6-Benz-cAMP) or EPAC activator (8-pCPT-2 0 -O-Me-cAMP) agents that also decreased HIF transcriptional activity. In addition, PDE4 inhibition suppressed induction of hypoxia-responsive genes such as LDHA, PDK1 and VEGFA. Interestingly, PDE4i led to decrease in the amount of secreted VEGF compared with A549 cells that were exposed to hypoxia. Hence, our study demonstrates pronounced crosstalk between HIF-a master regulator of hypoxic responses-and the PDE4 -cAMP pathway.
As PDE4 isoforms are overexpressed under hypoxic conditions and could be implicated in lung tumor progression, we first assessed the role of PDE4 isoforms in proliferation of lung cancer cells. We demonstrated that PDE4i or PDE4A/PDE4D silencing significantly decreased the proliferation and colony-forming abilities of lung cancer cells under hypoxia and normoxia, but the effects were more pronounced under hypoxia. In addition, we observed decreased expression of cyclin B1 and cyclin E in the presence of PDE4i. Most importantly, the anti-proliferative effects of PDE4 inhibition were observed in a panel of human lung cancer cells that included adenocarcinomas, large cell carcinomas and squamous cell carcinomas. This effect is intriguing and suggests the widespread therapeutic potential of PDE4i. These data are in agreement with previous studies that demonstrated anti-proliferative effects of PDE4 inhibition in human glioma, acute lymphoblastic leukemia and pancreatic cancer cells. In fact, the growth inhibitory effects of PDE4i appear to be celltype specific; in the melanoma cell line HMG, the PDE4i rolipram and Ro-20-1724 promote cell growth. 15 Consistent with these in vitro studies, PDE4i treatment showed significant anti-tumor efficacy on A549 human lung cancer xenografts in nude mice. To our knowledge, this is the first report to show a potential therapeutic role for PDE4 inhibition in the treatment of lung cancer. PDE4 is currently being developed as a novel therapeutic target for the treatment of asthma and chronic obstructive pulmonary disease. 30, 31 The anti-tumor effects of PDE4i are most readily attributed to decreased cell proliferation, as evidenced by decreased Ki67-positive cells. This can also be attributed to the anti-angiogenic potential of PDE4i as shown by the reduced number of CD31-positive vessels in lung tumors. This is of potential importance because angiogenesis in many solid tumors, including lung cancer, is a major factor in predicting disease aggressiveness and patient survival. 32 In addition, we have previously demonstrated that PDE4i attenuates the epithelialmesenchymal transition in A549 cells, 22 which has been hypothesized to be a critical event in the invasion and metastasis of tumor cells.
In summary, we report that PDE4 is a positive regulator of the hypoxia-HIF signaling pathway and has an important role in proliferation of several human lung cancer cell lines. PDE4 inhibition suppressed lung tumor growth in vivo by decreasing cell proliferation and angiogenesis. These findings suggest PDE4 as a novel 
MATERIALS AND METHODS
Cell lines
Human adenocarcinoma (A549, H1299, H1437, H1650, H1975 and H23), large cell carcinoma (H460 and H661) and squamous cell carcinoma (H226 and H520) cell lines were obtained from American Type Culture Collection (Table 1) 
RNA Interference
We used siRNA oligonucleotides specific for PDE4A, PDE4D, HIF1a, HIF2a and scramble siRNA (si-control). Sequences of siRNA are provided in data supplement. Transient transfection with siRNAs was performed with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocols. See online data supplement for details.
RNA isolation and real-time RT-PCR
Total RNA was extracted from the hypoxia-exposed and siRNA-treated cells with Trizol Reagent. Total RNA was reverse transcribed with ImProm-II Reverse Transcription System, followed by RT-PCR analysis of PDE4A, PDE4B, PDE4C, PDE4D, HPRT1, LDHA, PDK1 and VEGF. For details of protocol and primer sequences, see data supplement.
PDE activity assays PDE activity was determined with a radio enzymatic assay as described in data supplement. Total cAMP-PDE activity was assessed at 1 mM cAMP and the contribution of PDE4 isozymes was determined by using selective inhibitor-rolipram.
Immunoblotting
Immunoblotting was performed for detection of b-actin, HIF1a, HIF2a, PDE4A, PDE4D, VEGF, p27, cyclin E and cyclin B1 from protein lysates. See data supplement for details.
Construction of HRE plasmids and luciferase assay
The pmirGLO vector (Promega, Mannheim, Germany) was modified to test HRE sites that were predicted in silico within the 8 kb 5 0 upstream region of PDE4A (ENST00000344979) and PDE4D (ENST00000360047) genes. Initially, the polylinker was replaced by the fivefold tandem repeat of the PGK-HRE coupled to the HSV-TKmp promoter as described and analyzed. 33 The resulting plasmid served as a control construct and as origin for insertion of the predicted PDE4A and PDE4D HRE regions (NCGTG ± 12N) or its mutated control sequences (NAAAG±12N). A549 cells were transfected by Lipofectamine 2000. The dualluciferase analysis of promoter activities was performed according to the manufacturer's instructions (Promega) employing a Spectrofluorometer (BioTek Instruments GmbH, Bad Friedrichshall, Germany).
Proliferation assays
Proliferation assays were performed with tumor cells exposed to different experimental conditions: (i) tumor cells transfected with siPDE4A, siPDE4Dor both siPDE4A/siPDE4D, (ii) tumor cells transfected with plasmid construct encoding PDE4A, PDE4D or both PDE4A/PDE4D and (ii) tumor cells treated with PDE4i. After 20 h treatment, [ 3 H]thymidine or BrdU was added. Thymidine or BrdU incorporation was determined after 4 h by beta counter or ELISA reader, respectively, as described in data supplement.
Colony formation assays
Two hundred cells were seeded in a 60-mm culture dish followed 24 h later by incubation without or with PDE4i. After incubation for 10 days in normoxia and hypoxia, the colonies were stained with crystal violet, rinsed in water, airdried and photographed. Manual counting scored colonies containing more than 50 cells, and five plates were counted per treatment group.
Vascular endothelial growth factor (VEGF) measurement A549 cells were exposed to normoxia or hypoxia in the absence or presence of PDE4i. Cell supernatants were collected, clarified by centrifugation at 2000 r.p.m. for 5 min, and measured for VEGF concentration in the supernatant using an ELISA kit (R&D Systems, Minneapolis, MN, USA).
Animals
Immunodeficient female BALB/c nu/nu mice 7-8 weeks old were purchased from Charles Rivers (Sulzfeld, Germany), kept under pathogen-free conditions, and handled in accordance with the European Communities recommendations for experimentation.
Tumorigenicity in nude mice
Tumorigenicity was assessed by subcutaneous injection of A549 cells (5 Â 10 6 cells/200 ml in saline) into female BALB/c nu/nu mice. Treatment was initiated when tumors were 35.95±3.71 mm 3 . The selective PDE4i rolipram (1, 3 and 6 mg/kg, with vehicle (DMSO) as a control) was administered s.c. once daily for 36 days. Tumor size was calculated using the equation: length Â (width)
2 )/2 as described. 34 After 36 days of treatment, the mice were anesthetized for imaging and killed.
Immunostaining A549 cells grown on chamber slides were treated and fixed with acetonemethanol (1:1). After blocking with 5% BSA, cells were incubated with the following primary antibodies, PDE4A, PDE4D, HIF1a and HIF2a. Indirect immunofluorescence was conducted by incubation with Alexa 488-conjugated secondary antibodies (Molecular Probes Inc., Eugene, OR, USA). For immunohistochemical staining, consecutive 5 mm cryostat s.c. tumor sections were fixed with acetone-methanol and then hydrated in PBS. Tissues were blocked in 5% BSA/PBS and incubated with primary antibody against proliferating cell nuclear antigen (Ki67) or CD31. For indirect immunofluorescence, slides were incubated with Alexa Fluor 488-labeled secondary antibodies. After incubation, all sections were counterstained with DAPI (for nuclear staining) and mounted with fluorescent mounting media (Dako Cytomation, Glostrup, Denmark). At the end of the procedure, fluorescence images were acquired. Details of imaging parameters and the fluorescent intensity quantified as described in data supplement.
Data analysis
All graphs and statistical procedures were done using GraphPad 5 (San Diego, CA, USA). The analysis of variance one-way test followed by the Dunnett post hoc was used for data analysis. Data are expressed as mean±s.e. Statistical significance was set at Po0.05. 
